Compare Quest Diagnostics Inc (DGX) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $60.41 (market cap $77.43B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 3× Quest Diagnostics Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.43%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and MONDELEZ INTERNATIONAL INC Common Stock for 107 Days on average.
| DGX | MDLZ | |
|---|---|---|
Market Cap | $25.48B | $77.43B |
Volume | 941,866 | 7,695,104 |
Sector | Health | Consumer Staples |
52-Week High | $247.45 | $64.99 |
52-Week Low | $173.49 | $51.51 |
Typical Hold Time | 56 Days | 107 Days |
Enterprise Value | $31.23B | $97.78B |
Dividend Yield | 1.49% | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Mondelez International (MDLZ) trades at $60.67, up 2.17% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats with Q2 2026 EPS of $0.73 exceeding expectations. Recent dividend increase to $0.52 per share and positive cash flow trends support the investment case. Valuation metrics include P/E of 22.22 and P/S of 1.97, while revenue growth continues with 2025 revenue reaching $38.54 billion.
MDLZ presents a compelling opportunity with 76% analyst buy ratings and $70.29 consensus price target representing 16% upside. The company demonstrates pricing power and emerging market momentum, though cocoa cost pressures and margin compression from 13.76% in 2023 to 6.36% in 2025 remain key watchpoints. Strong brand portfolio and defensive characteristics provide stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
